What is Semax?

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A synthetic 7-amino-acid fragment of ACTH, used as a nootropic and neuro-repair peptide. It's non-stimulating.

Mechanism (as described)

• Raises BDNF and NGF quickly, and pushes neural stem cells to become working neurons (hippocampus, cortex).
• Strengthens dendrites, axons and synaptic plasticity. Supports dopamine/serotonin signaling and protects dopamine neurons.
• Alzheimer's-related: shifts APP processing toward the non-amyloid path and raises neprilysin (amyloid breakdown).
• Lowers CNS inflammation (immunomodulator, cited in MS), aids vessels and antioxidants, and boosts stress resilience.

Additional points (as described)

• Binds MC3/MC4 receptors and switches on BDNF/NGF genes: building structure rather than stimulating.
• Also listed: brain glucose transport, PGC-1α, glutathione; raises tyrosine hydroxylase (dopamine) in Parkinson's; shifts immune balance toward Tregs and supports myelin-cell maturation in MS.
• In fibromyalgia it's used to reset HPA and cortisol rhythm and for POTS.
• Long clinical use in Russia (stroke) is cited for safety.
• Cognitive-decline team: Semax (directs), Cerebrolysin (supplies neurotrophic factors), alpha-GPC (choline), BPC-157 (vessels, gut), GHK-Cu (gene reset).

FDA Compounding Panel (July 2026)

At its July 23-24, 2026 meeting, the FDA Pharmacy Compounding Advisory Committee recommended adding Semax (free base and acetate) to the Section 503A bulks list, for the uses FDA reviewed (cerebral ischemia, migraine and trigeminal neuralgia). FDA's own briefing documents had proposed not adding it.

• The vote is advisory and non-binding. It is not FDA approval, and it does not by itself allow pharmacies to compound Semax. FDA would have to finish rulemaking to change the final list (21 CFR 216.23), which included no peptides as of October 2026.
• Reported tally (yes-no-abstain): 8-5-1, as reported in law-firm meeting reports. FDA had not posted official minutes or vote results when checked on October 19, 2026.
• FDA: July 23-24, 2026 PCAC meeting materials (substances under consideration)
• FDA: July 23-24, 2026 PCAC final agenda
• eCFR: 21 CFR 216.23, the final 503A bulks list